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ported data. The objective of this study was to estimate persistence to oral bispho-
sphonates (OBPs) in the Portuguese postmenopausal osteoporosis (PMO) popula-
tion, exploring different methods. METHODS: This was an observational,
prospective cohort study of women 50 years old with PMO who had not been
prescribed PMO treatment within 6 months prior to recruitment from community
pharmacies. Patients were classified as persistent if they refilled their prescription
within a 30-day grace period after exhausting the time covered by their previous
supply. For subgroup analysis, non-persistent patients were followed up by tele-
phone. Sensitivity analysis included 6 different methods, in particular, increasing
the grace period to 90 days and allowing a switch to other PMO medication.
RESULTS: A total of 427 women (mean age 65 years) were included in the analysis.
Persistence rates at 6 months of follow-up (interim analysis) varied from 27.6%
(95%CI 23.4%-32.0%) to 52.6% (95%CI 47.3%-57.6%) using pharmacy records exclu-
sively and additional patient report of BP acquisition in a different pharmacy (re-
ported by 113 of 269 patients), respectively. Allowing a longer grace period (90 days)
and switch to other PMO medications resulted in rates of 49.9% (95%CI 33.8%-64.0%)
and 28.6% (95%CI 24.3%-33.0%), respectively. CONCLUSIONS: Results at 6 months
showed a variation in persistence rate estimates depending on the method applied,
with increased estimates when self-reported data and longer grace periods were
used. Ongoing analysis will allow assessment of the impact of the different meth-
ods over longer follow-up periods.
PMS58
FREQUENCY OF ADMINISTRATION OF BIOLOGICS HAS AN IMPACT ON
TREATMENT DECISION MAKING
Chevalier P1, Black CM2, Lamotte M3, Crombach J4, Huismans J4, Rosiek R5, Fan T6
1IMS Health, Vilvoorde, Belgium, 2St. John’s University, Queens, NY, USA, 3IMS Health
Consulting Group, Vilvoorde, Belgium, 4Merck Sharp & Dohme Netherlands, Haarlem, The
Netherlands, 5Medithuis B.V., MAARSSEN, BB , The Netherlands, 6Merck & Co. Inc., Whitehouse
Station, NJ, USA
OBJECTIVES: To document the real-life use of golimumab in patients with Anky-
losing spondylitis (AS), Rheumatoid arthritis (RA) and Psoriatic arthritis (PsA), in
terms of treatment persistence/ discontinuation, adherence and switching
patterns. METHODS: This study was a single country (the Netherlands), retrospec-
tive database study of AS, RA and PsA patients treated with golimumab from March
17, 2010 onwards with last data collection being performed on October 3rd 2011.
RESULTS: The sample consisted of 882 patients (163 with AS, 216 with PsA and 503
with RA; 33% being male patients) with a maximum follow-up period of 57 weeks.
Forty-eight percent (n422) were naïve patients, while 52% (n460) were switched
from a previous anti-TNF treatment; 37% were previously treated with etanercept
and 38% with adalimumab, with no significant difference between the three indi-
cation groups. Among the switched patients, the main reason for switching to
golimumab were the lack of efficacy of the previous treatment (30.9%), the more
convenient frequency of administration with golimumab (27.0%) and unspecified
side-effects (18.8%). Temporary treatment discontinuation of golimumab was ob-
served in only 1.25% of the patients (n11). For these patients, adherence ranged
between 31.82% and 93.72%. The median time-to-dropout or median persistence
was 195 days when calculated in the whole population (n882). Sex and type of
patient (“naïve” vs. “switcher”) were identified as predictors, with a hazard ratio of
0.693 associated to male patients (vs. female patients; p-value0.014) and of 0.596
associated to naïve patients (vs. switchers; p-value0.001). CONCLUSIONS: Con-
venient frequency of administration has an impact on treatment decision making.
Sex and type of patient (“naïve” vs. “switcher”) were identified as predictors of
switch, with male patients and naïve patients associated with a higher persistence
to golimumab.
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OBJECTIVES: Comorbidities can influence generic measurement of health by
multi-attributes or indirect utility. We investigated the impact of comorbidities to
assess indirect utility with the Medical Outcomes Study Short Form 6D (SF-6D)
measuring health-related quality of life in patients with osteoarthritis (OA).
METHODS: The 878 patients, aged 45-75 years with symptomatic knee or/and hip,
of the KHOALA (Knee and Hip OsteoArthritis Long term assessment) cohort were
included in the study. Comorbidities were assessed by the Functional Comorbidity
Index (FCI) and grouped in 9 categories. Limitation in activities and pain was mea-
sured by the Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC).Two separate linear regression models, using the number of comorbidi-
ties or the different categories of comorbidities of the FCI, were fitted to determine
predictors of utility score. RESULTS: For the 878 patients included, the mean (SD)
utility score was 0.66 (11; range 0.32–1.00) and mean number of comorbidities 2.05
(1.58). In the first multivariate model, , for each additional comorbidity (range 0–9) the
mean utility score decreased of 0.01 point (beta -0.010, p0.0001). In the second
model, including comorbidities by categories, only psychiatric disease (beta-
0.043, p0.0001) and degenerative disc disease (beta-0.014, p0.018) predicted
low utility score. In both regression models a worsened function (increased
WOMAC function score) significantly decreased the utility score. The number of
comorbidities explained 2% of the variance in utility score (partial R-square0.02)
and psychiatric and degenerative disc diseases explained 2% (partial
R-square0.025) and 0.7% (partial R-square0.007), respectively, of the variance in
utility score, whereas the WOMAC function score explained 38% of the variance in
both models (partial R-square  0.38). CONCLUSIONS: Compared to greater nega-
tive effect of functional impairment, comorbidities have a negative but relatively
marginal impact on indirect utility score. This suggests that clinically, considering
the functional severity of OA remains a first priority.
PMS60
THE TIME HORIZON MATTERS: EXPLORATORY RESULTS VARYING THE TIME
HORIZON IN TIME TRADE-OFF AND STANDARD GAMBLE UTILITY ELICITATION
Matza L1, Boye KS2, Feeny DH3, Bowman L2, Johnston JA2, Mcdaniel K1, Jordan J1, Devine
MK1, Davies E4
1United BioSource Corporation, Bethesda, MD, USA, 2Eli Lilly and Company, Indianapolis, IN,
USA, 3University of Alberta, Portland, OR, USA, 4United BioSource Corporation, London, UK
OBJECTIVES: In time trade-off (TTO) and standard gamble (SG) procedures for elic-
iting health state utilities, the duration of time spent in each health state is an
integral component of the task. The most common time horizon is 10 years, but
others are used, including personalized time horizons which aim to present real-
istic choices reflecting reasonable expectations of the respondent’s lifespan. The
purpose of this study was to examine implications of the time horizon used in
direct utility assessment.METHODS:UK general population participants rated four
health states (describing osteoarthritis) with a Visual Analog Scale (VAS), followed
by TTO and SG procedures with a 10-year time horizon. Half of the sample was
randomized to complete utility procedures again with a personalized time horizon
based on self-reported additional life expectancy. Scores were compared in terms
of discrimination between health states. RESULTS: The 10-year tasks were com-
pleted by 80 participants (mean age 47.3; 48.8% female), and 35 also completed
personalized time horizon procedures. Nearly all participants (97.5%) rated health
state A (mild osteoarthritis) higher than B (moderate) on the VAS. However, the
10-year tasks did not consistently detect this ranking, with only 32.5% (TTO) and
23.1% (SG) of respondents distinguishing between health states. The personalized
time horizon resulted in increased rates of discrimination between health states:
54.3% with both TTO and SG. This increase was statistically significant (TTO: chi-
square 4.9; p 0.03; SG: chi-square 10.7; p 0.001). Two other health state pairs
followed similar patterns, but without statistically significant differences between
time horizons. CONCLUSIONS: In this exploratory study, the personalized time
horizon resulted in better discrimination between health states than the fixed
10-year approach. When designing utility evaluations, researchers should carefully
consider the time horizon so that the relative value of health states are accurately
represented in cost-utility models.
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OBJECTIVES: To compare health utility estimated with the EQ-5D and the Time-
trade-off (TTO) instruments after vertebral fracture. METHODS: The International
Costs and Utilities Related to Osteoporotic fractures Study (ICUROS) is a prospec-
tive multinational study with the aim of estimating costs and health related quality
of life (HRQoL) related to osteoporotic fractures. In the study, two instruments were
used to estimate patients’ perceived health utility: the direct individual preference
based TTO instrument and the indirect EQ-5D instrument, valued by societal pref-
erences. Health utility was measured before fracture (recollection), and 2 weeks, 4
months and 12 months after fracture. RESULTS: In the 225 patients included in the
interim analysis, estimates of health utility elicited from the two instruments var-
ied significantly and the EQ-5D systematically provided lower estimates compared
to the direct TTO instrument. The smallest mean outcome difference was 0.10
(TTO: 0.91 and EQ-5D: 0.81), elicited before fracture and the largest difference was
0.20 (TTO: 0.44 and EQ-5D: 0.23), elicited after two weeks. The correlation coeffi-
cient for the health utility loss over 12 months, using Spearman’s correlation, for
the two instruments was 0.36 (p0.05). CONCLUSIONS: Osteoporotic vertebral
fractures give rise to significant loss of health utility, irrespective of instrument
used. However, there are substantial differences in the extent of the health utility
decrease assessed by the two instruments. The main explanation for these differ-
ences is that the instruments rely on different reference populations; respondents
of direct TTO act as their own reference and express preferences regarding their
own health state, whereas the EQ-5D reflects the preferences of healthy individuals
assessing hypothetical health states.
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OBJECTIVES: The selection of attributes represents an important step in the devel-
opment of discrete-choice experiments (DCE), but is often poorly reported. In some
situations, the number of identified attributes may exceed what one may find
possible to pilot in a DCE. Hence there is a need to gain insight into methods to
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